Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A bad news pr sends RGBPP into a sell off but RGBP is green.Makes you wonder.
CAR-T has had recent success.Juno and Kite along with Novartis
https://www.yahoo.com/finance/news/car-t-kite-juno-novartis-000000573.html
Sometimes, a cancer patient just knows when enough is enough. Robert Legaspi, 27, was diagnosed with acute lymphoblastic leukemia (ALL) when he was 9 years old. Since then, his cancer has recurred several times. The chemotherapy regimens have been long and brutal, and it’s taken two years each time for him to get back into remission.
When Legaspi’s cancer returned for the fourth time earlier this year, his oncologist, Dr. Ted Ball at Moores Cancer Center at UC San Diego Health, asked him if he’d be interested in trying an experimental new treatment that would harness his own cells to fight the cancer.
Ball expressed to Legaspi that there were some potential serious side effects in this treatment including neurotoxicities.
Its the Botox talking :)
Regen BioPharma, Inc. Files Composition of Matter Patent Application on NR2F6 Modulating Small Molecules
Small Molecule Screening Program Begins to Bear Fruit
http://www.otcmarkets.com/stock/RGBP/news/Regen-BioPharma--Inc--Files-Composition-of-Matter-Patent-Application-on-NR2F6-Modulating-Small-Molecules?id=136736&b=y
PR Newswire
SAN DIEGO, July 27, 2016
SAN DIEGO, July 27, 2016 /PRNewswire/ --
Regen BioPharma, Inc., (OTCQB: RGBP) and (OTCQB: RGBPP) today announced the filing by the Company of a patent application with the United States Patent and Trademark Office covering composition of matter and methods of use related to molecules that activate and inhibit NR2F6 which have been identified in Regen's small molecule program.
NR2F6 is a molecular switch known as an "orphan nuclear receptor", which controls genes associated with the immune response as well as genes associated with the ability of cancer stem cells to propagate. Regen has filed numerous patent applications covering means of manipulating NR2F6 in oncology and immunology. Regen already has an issued US Patent was assigned covering means of screening small molecules such as the ones identified in the most recent patent application filed by Regen.
"As molecules and families of molecules are identified in our screening program, we will actively and vigorously protect our intellectual property. We expect to have more of these types of filings as we identify more molecules and further refine them," said Harry M. Lander, Ph.D., President and Chief Scientific Officer. "What is unique about NR2F6 is that it is a novel target that modulates the immune system for which no known molecules that bind to it exist. Ours are likely the first ever identified."
Activators of NR2F6 have the potential to tap into the autoimmune disease markets and inhibitors of NR2F6 will target the cancer market.
"This is Regen's first big step towards creating an oral drug that targets the NR2F6 molecule. We still have lots of work to do to get this into humans, but it is a critical first step," said David Koos, Ph.D., Chairman & CEO of Regen BioPharma, Inc.
About Regen BioPharma, Inc.
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The company aims to rapidly advance these technologies through pre-clinical and Phase I/II clinical trials. Currently the company is focusing on checkpoint inhibitor and gene silencing therapies for treating cancer, along with developing stem cell treatments for aplastic anemia.
I dont buy it.With the pps for RGBPP at a premium it would make no sense to give RGBP premium status.At current prices the company would give .10 for every 3.40 RGBPP. Not to mention the dilution factor.We dont need gimmics,just solid results from the clinical trial and fda approval for clinicals on the rest of the pipeline.Until one of those happens then we are stuck at the start line.
IMO RGBPP has more value bc of the voting shares and bc they are preferred shares.
Up 23% today thats very interesting.Alot of companies looking to buy up smaller firms to shore up their pipelines.
Very nice.I too think we are going to breakout as we get closer to September.
I guess that you didnt fill out the order AON.
Flexus is a subsidiary of Bristol Myers Squibb.
http://news.bms.com/press-release/rd-news/bristol-myers-squibb-expand-its-immuno-oncology-pipeline-agreement-acquire-fle
Thanks I missed that.
No update on Clinical trials underway in Mexico ? Thats quite odd.
If so they will begin phase II trials.
It would appear that RGBP and Lily are forming quite a nice partnership,one with deep pockets.Here is more info on the Lilly program.
https://openinnovation.lilly.com/dd/
Thanks !!
Link ?
I hope this up trend continues.No news this week so far,but one has to think the company is sitting on very good news.
Yes I do
Red Monday
Wow RGBP pps has passed RGBPP !! You may be right about big news in the offing.
We need a clinical trial update ASAP !!
up 37% today at .11 I wonder whats up ?
Its funny I dont feel like a bag holder.I have never lost money on a biotech stock.I dont care if I have to hold this another year,the wait is worth it IMO.
The company did retain a M&A house to obtain a partner to fund the pipeline as it moves toward FDA approval for human trials.
RGBP has made steady progress.Maybe when phase 1 trials are successful and move on to phase 2 we will finally see upward movement.I am encouraged by the progress the company has made but it is not reflected by the stock price.
Article which explores the view of Dr Pazdur FDA Oncology Products.He thinks too many companies are chasing the same cancer strategy.Perhaps RGBP's focus might be an approach that he would support ?
https://www.yahoo.com/news/u-regulator-says-too-many-drugmakers-chasing-same-204954289--finance.html
CHICAGO (Reuters) - A new type of cancer drug that takes the brakes off the body's immune system has given drugmakers some remarkable wins against the deadly disease, but a top U.S. regulator says too many companies are focused on the same approach.
Dr. Richard Pazdur, head of the Food and Drug Administration's office of oncology products, was referring to therapies designed to disable the PD-1 protein that tumors use to evade the immune system.
The FDA has approved such treatments from Merck & Co , Bristol-Myers Squibb Co and Roche Holding AG , each of which have list prices of $150,000 per year. At least five other drugmakers are developing similar medicines.
"People should ask themselves ... would we be better off spending those resources into looking at more novel drugs?" Pazdur told Reuters during the annual American Society of Clinical Oncology (ASCO) meeting in Chicago this week.
Makes sense.Thanks
We had massive volume today and yet the pps didnt breakout.We had great news and yet no movement on the price.Any opinions ?
This is the only stock that I have seen drop on good news.Definitely a mystery to me.
This might send this stock to dollar land.Very good PR !!
Thanks
Why is the last quote from 1.03pm ? Did the market close early ?
First time I have heard loan shark associated with an M&A shop.These companies are always involved in major corporate mergers and acquisitions.They act more like an MM does.They are well worth the money they receive for their expertise.
We still need FDA approval to play in the US drug market.Even China has its version of the FDA.Another problem when dealing in foreign markets is how to protect your intellectual property.
I would rather see a revenue stream from licensing of each product.Right now for these new immunotherapies the cost per dose is over $150,000 and up why give that up ?
We cannot be far away from further FDA approvals.
Yep it would be a good way to raise funds by selling or licensing Hema.
You forgot the M - mergers.
Cancer vaccine as reported in the link,is also a goal of RGBP.
http://nextbigfuture.com/2016/06/bodys-immune-system-induced-to-attack.html
Koos might be able to buy a bigger boat.:)